Compugen Prepares for SITC Presentation on Breakthrough Cancer Immunotherapy COM503

Compugen Advances Cancer Immunotherapy with Upcoming Presentation

Compugen Ltd., a clinical-stage cancer immunotherapy company based in Holon, Israel, reaches a significant milestone as it prepares to present groundbreaking findings from its first human trial of the anti-IL18BP antibody, COM503 (GS-0321). Scheduled for November 7, 2025, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland, this presentation marks a pivotal moment for the company as it seeks to validate its innovative approaches to cancer treatment. The trial, which focuses on participants with advanced solid malignancies, showcases Compugen’s commitment to developing novel therapeutic strategies aimed at enhancing immune responses against cancer.

Dr. Manish Sharma, Co-Director of Clinical Research at START Midwest, will present the abstract detailing the trial's findings. The study investigates the safety and efficacy of COM503, a high-affinity antibody targeting the IL-18 binding protein. This therapy is part of Compugen's broader mission to leverage its predictive AI and machine learning platform, Unigen™, to identify and develop new drug targets tailored for cancer immunotherapy. The company emphasizes the importance of this research within the context of a rapidly evolving landscape of cancer treatments, where the identification of effective immunotherapies is crucial for improving patient outcomes.

In addition to COM503, Compugen’s pipeline includes two other proprietary candidates—COM701 and COM902—both currently in Phase 1 development. These candidates target PVRIG and TIGIT, respectively, which are vital checkpoints in the immune response to cancer. Furthermore, the company maintains a strategic partnership with AstraZeneca for Rilvegostomig, a bispecific antibody that combines PD-1 and TIGIT targeting, which is already in Phase 3 development. This collaborative approach underscores Compugen’s commitment to advancing the frontiers of cancer immunotherapy through innovative research and strategic alliances.

Compugen's operations extend beyond its Israeli headquarters, with a significant presence in San Francisco, CA. As the company continues to push the boundaries of cancer treatment, its dual focus on proprietary drug development and partnerships with established pharmaceutical giants positions it well within the competitive landscape of immuno-oncology. The upcoming presentation at SITC is anticipated to generate interest and further discussions around the potential of the anti-IL18BP antibody in clinical settings, reflecting the company's strategic vision in addressing unmet medical needs in cancer care.